一个甲状腺乳头状癌家系中的CHEK2胚系突变
约5%的甲状腺乳头状癌(PTC)为遗传性,但非综合征型家族性PTC(FPTC)的易感基因尚不明确。研究对一个FPTC家系行全基因组测序,发现CHEK2新发杂合胚系突变c.417C→A(Y139X),该突变在公共数据库264200人中仅1例;携带者肿瘤中CHK2蛋白表达降低,p53磷酸化及蛋白水平下降。242例散发PTC中另见5例(2%)CHEK2罕见错义变异。作者提示CHEK2 Y139X可能与FPTC相关。
要点
- 在FPTC家系中发现CHEK2胚系突变c.417C→A(Y139X),该突变在264200人中仅1例。
- 携带该突变的2例患者肿瘤中CHK2蛋白表达低于无该变异的散发PTC病例。
- Y139X功能缺失变异导致p53磷酸化减少及p53蛋白水平降低。
核心结论
- 作者认为CHEK2 Y139X变异可能与家族性甲状腺乳头状癌相关。
研究设计与样本
- 对一个家族性甲状腺乳头状癌家系中2例患病成员的外周血DNA行全基因组测序。
- 对家系中2例患病成员及散发PTC病例的甲状腺组织评估CHEK2转录表达及CHK2、p53蛋白水平。
- 对242例散发PTC患者血DNA行CHEK2全编码序列Sanger测序。
主要发现
- 在一个FPTC家系的所有可获取患病成员中检出CHEK2新发杂合胚系突变c.417C→A。
- 该变异在Genome Aggregation Database与NHLBI Trans-Omics for Precision Medicine项目的264200人中仅1例。
- CHEK2 c.417C→A变异引入提前终止密码子Y139X。
- 携带该变异的2例患者肿瘤样本中CHK2蛋白表达低于不携带该变异的散发PTC病例。
- Y139X功能缺失变异导致p53磷酸化减少及p53蛋白水平降低;242例散发PTC中5例(2%)检出CHEK2罕见错义变异R180C和H371Y。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Approximately 5% of all cases of papillary thyroid cancer (PTC) are inherited. However, the susceptibility gene(s) for nonsyndromic familial PTC (FPTC) remain unclear. We performed whole genome sequencing of peripheral blood DNA samples from two affected family members with PTC. CHEK2 transcript expression and the protein levels of CHK2 and p53 were evaluated in the thyroid tissues from two affected members of the kindred and sporadic PTC cases. The entire CHEK2 coding sequence was examined by Sanger sequencing in blood DNA samples from 242 sporadic PTC patients. We identified a novel heterozygous germline mutation in CHEK2 (c.417C→A) that was detected in all available affected members of a kindred with FPTC. This variant was found in only 1 out of 264,200 persons in the Genome Aggregation Database and the NHLBI Trans-Omics for Precision Medicine program. The CHEK2 c.417C→A variant introduces a premature termination codon (Y139X). We found reduced CHK2 protein expression in tumor samples from the two patients who carried the variant as compared with sporadic cases without the variant. The Y139X loss-of-function variant led to reduced p53 phosphorylation and decreased p53 protein level. In addition, two rare missense variants (R180C and H371Y) in CHEK2 were identified in 5 (2%) of 242 patients with sporadic PTC. Our findings suggest that the CHEK2 Y139X variant may be associated with FPTC.
引用
- Zhao Y, Yu T, Chen L, et al. A Germline CHEK2 Mutation in a Family with Papillary Thyroid Cancer. Thyroid. 2020. PMID: 32041497. doi:10.1089/thy.2019.0774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。